The allocations provided by the Global Fund to countries for 2014-2017 amount to $14.67 billion. The breakdown by type of component is as follows: HIV 52% ($7.64 billion), malaria 29% ($4.26 billion), TB 17% ($2.50 billion) and health systems strengthening 2% ($281 million).

A letter, signed by over 100 clinicians, organisations and patients with DR-TB, demands the immediate registration of a generic version of linezolid in South Africa, which has been under a significantly delayed fast-track review process since May 2013.

The three new fact sheets on “Ambulatory TB care”, “Integrated TB/HIV care” and “Engaging civil society and affected communities in the fight against TB” aim to share best practices from the European region on the three topics.

New treatment regimen is first-ever injection-free regimen tested to date.

We need support to train, equip and empower civil society leaders to form a movement that stretches both within and beyond national borders.

Today TB activists interrupted the plenary session at the 45^th Conference on Lung Health, calling on the Global Fund and partners to increase the amount of funds allocated to TB without jeopardizing funding to HIV and malaria and other diseases.

TB activists interrupted Otsuka’s symposium at the 45^th Conference on Lung Health, calling for widespread registration of and immediate broad compassionate use access to delamanid, Otsuka’s new drug to treat multidrug-resistant TB.

For the first time, the World Health Organization has issued guidelines on testing, treating and managing latent TB infection in individuals with high risk of developing disease.

Outmoded policies and practices and critical gaps in care for drug-resistant TB are fuelling a worldwide public health crisis, said MSF in a new report, ‘Out of Step: Deadly implementation gaps in the TB response’, released today at the 45^th Conference on Lung Health in Barcelona.

Today at the opening plenary of the 45^th Conference on Lung Health in Barcelona, activists from across the globe called on governments to dramatically increase spending on R&D for new treatments for TB. Spending must be tripled to meet the US$2 billion annual minimum required according to the Stop TB Partnership’s Global Plan to Stop TB.